Eriko Tokunaga - Concepedia

Author

Eriko Tokunaga

Also Known As

E Tokunaga, E. K. Tokunaga, E. Tokunaga, ERIKO TOKUNAGA, Eiichi TOKUNAGA, Eriko TOKUNAGA, Eriko Tokunaga, M Basik, Tokunaga, Eriko, Tsutomu Iwasa

361

Publications

13.2K

Citations

H-Index

112

Concepts

All Affiliations

Kyushu University National Hospital Organization Kyushu Cancer Center Memorial Sloan Kettering Cancer Center Samsung Medical Center Kanagawa Prefectural Hospital Organization

About

Eriko Tokunaga is an author at Kyushu University specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	62	4.4K
2	Health Sciences	13	13	1.1K
3	Engineering	11	11	988
4	Natural Sciences	5	5	294
5	Nursing	2	2	58

Eriko Tokunaga

121

Publications

12.2K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi, Cristina Saura, Toshinari Yamashita, New England Journal of Medicine	2019	1.9K
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, New England Journal of Medicine	2023	600
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells Hidetaka Ota, Eriko Tokunaga, Kyungho Chang, Oncogene Tumor BiologyAttenuated Ras–mapk SignalingCell RegulationMedicineCancer Cell Biology	2005	430
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer Yoshihiko Maehara, Shota Hasuda, Tadashi Koga, British journal of surgery	2000	268
S-Nitrosylation-dependent Inactivation of Akt/Protein Kinase B in Insulin Resistance Takashi Yasukawa, Eriko Tokunaga, Hidetaka Ota, Journal of Biological Chemistry	2005	255
Topochemical synthesis and catalysis of metal nanoparticles exposed on crystalline cellulose nanofibers Hirotaka Koga, Eriko Tokunaga, Mami Hidaka, Chemical Communications Materials ScienceTopochemical SynthesisChemical EngineeringNanofiberEngineering	2010	227
Activation of PI3K/Akt signaling and hormone resistance in breast cancer Eriko Tokunaga, Yasue Kimura, Kojiro Mashino, Breast Cancer Tumor BiologyBreast OncologySignal TransductionSignaling PathwayMedicine	2006	199

Page 1